Will Pfizer rebid for AstraZeneca? Keep an eye on U.S. midterm election for clues

Will Pfizer ($PFE) come back at AstraZeneca ($AZN)? That's been the question of the summer, especially since the U.S. Treasury Department rolled out new rules for tax-inversion deals. Now, sources are telling the Financial Times and CNBC that the collapse of AbbVie's ($ABBV) buyout of Ireland-based Shire ($SHPG) make another Pfizer bid unlikely. Unless the midterm elections go against President Obama, that is. Report | Report

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.